Abstract
Malaria is one of the most common parasitic infections worldwide. Plasmodium falciparum is the most prevalent strain in Africa and also the most fatal. The disease especially affects children, with those under age 5 years accounting for approximately 86 % of malaria deaths in 2010. The objectives of this review are to summarize and evaluate published literature reporting the pharmacokinetic parameters of artemisinin-based combinations used to treat P. falciparum in paediatric populations and to identify and discuss controversies regarding pharmacokinetics of these agents in children. A search of MEDLINE (1948–September 2012), EMBASE (1980–September 2012), International Pharmaceutical Abstracts (1970–September 2012), Google and Google Scholar was conducted for articles describing pharmacokinetics of antimalarials in children. Our search produced 30 articles, of which 23 were included in the review: artemisinin compounds, 12 articles; lumefantrine, four articles; amodiaquine, five articles; sulfadoxine, six articles; pyrimethamine, one article; mefloquine, three articles; and piperaquine, two articles. Studies were summarized based on comparison groups and major findings. Many controversies were identified, including pharmacokinetic equivalence of novel dosage forms, altered pharmacokinetic parameters in children versus adults, effect of drug interactions, and association of pharmacokinetic changes with clinical outcomes. A large variation in pharmacokinetic parameters of many antimalarial agents was shown, which may be a consequence of the wide range of ages and/or bodyweights of each paediatric cohort. These studies may mask important associations with age and bodyweight and produce mean data that do not adequately represent the paediatric population as a whole. In order to properly assess the clinical implications of such pharmacokinetic changes and recommend safe and effective dosage regimens, there is an urgent need for dose-optimization studies for all recommended first- and second-line agents, along with the different drug formulations, used in paediatric populations with P. falciparum.
Similar content being viewed by others
References
World Health Organization. World malaria report 2011. http://www.who.int/malaria/world_malaria_report_2011/en/index.html. Accessed 23 Jul 2012.
World Health Organization. Guidelines for the treatment of malaria. 2nd ed. http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf. Accessed 12 Jul 2012.
World Health Organization. WHO model list of essential medicine for children 2011. http://whqlibdoc.who.int/hq/2011/a95054_eng.pdf. Accessed 30 Nov 2012.
Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002;66(2):185–200.
US Preventative Services Task Force. Guide to clinical preventative services: report of the US Preventive Services Task Force. 2nd ed. Baltimore: Lippincott Williams & Wilkins; 1996.
Deen JL, von Seidlein L, Dondorp A. Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop Med Inter Health. 2008;13(9):1111–30.
Schlagenhauf P, Adamcove M, Regep L, et al. Use of mefloquine in children: a review of dosage, pharmacokinetics and tolerability. Malaria J. 2008;10(292):1–11.
Mercer AE, Sallah MS. The pharmacokinetic evaluation of artemisinin drugs for the treatment of malaria in paediatric populations. Expert Opin Drug Metab Toxicol. 2011;7(4):427–39.
Nealon C, Dzeing A, Muller-Romer U, et al. Intramuscular bioavailability and clinical efficacy of artesunate in Gabonese children with severe malaria. Antimicrob Agents Chemother. 2002;46(12):3933–9.
Sidhu JS, Ashton M, Huong NV, et al. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol. 1998;45:347–54.
Djimde AA, Tekete M, Abdulla S, et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2011;55(9):3994–9.
Stepniewska K, Taylor W, Sirima S, et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malaria J. 2009;8:200. doi:10.1186/1475-2875-8-200.
Ramharter M, Kurth FM, Belard S, et al. Pharmacokinetics of two paediatric artesunate-mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. J Antimicrob Chemother. 2007;60:1091–6.
Ramharter M, Kurth FM, Schreier AC, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008;198:911–9.
Mwesigwa J, Parikh S, McGee B, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010;54:52–9.
Batty KT, Salmon S, Moore BR, et al. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study. Antimicrob Agents Chemother. 2012;56(5):2472–84.
Bethell DB, Teja-Isavadharm P, Phuong CXT, et al. Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 1997;91:195–8.
Hietala SF, Martensson A, Ngasala B, et al. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2010;54(11):4780–8.
Mithwani S, Aarons L, Kokwaro GO, et al. Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. Br J Clin Pharmacol. 2004;57(2):146–52.
Adjei GO, Kristensen K, Goka BQ, et al. Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother. 2008;52:4400–6.
Hombhanje FW, Hwaihwanje I, Tsukakara T, et al. The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol. 2005;59(3):298–301.
Wang P, Read M, Sims PF, et al. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol. 1999;23:979–86.
Barnes KI, Little F, Smith PJ, et al. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. J Clin Pharm Ther. 2006;80(6):582–96.
Obua C, Hellgren U, Ntale M, et al. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br J Clin Pharmacol. 2008;65(4):493–501.
Winstanley PA, Watkins WM, Newton CRJC, et al. The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br J Clin Pharmacol. 1992;33:143–8.
Dzinjalamala FK, Macheso A, Kublin JG, et al. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob Agents Chemother. 2005;49:3601–6.
Bell DJ, Nyirongo SK, Mukaka ME, et al. Population Pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. Clin Pharmacol Ther. 2011;89(2):268–75.
Price R, Simpson JA, Teja-Isavatharm P, et al. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob Agents Chemother. 1999;43(2):341–6.
Nosten F, Kuile F, Chongsuphajaisiddhi T, et al. Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. Br J Clin Pharmacol. 1991;31:556–9.
Bourahla A, Martin C, Gimenez F, et al. Stereoselective pharmacokinetics of mefloquine in young children. Eur J Clin Pharmacol. 1996;50:241–4.
Tarning J, Ashley EA, Lindegardh N, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother. 2008;52:1052–61.
Tarning J, Zongo I, Some FA, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91:497–505.
Adbulla S, Sagara I, Borrmann S, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomized, single-blind, multicentre trial. Lancet. 2008;372:1819–27.
Hietala SF, Bhattarai A, Msellem M, et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn. 2007;34:669–86.
Hellgren U, Kihamia CM, Bergqvist Y, et al. Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro. Trans R Soc Trop Med Hyg. 1990;84:469–73.
Borrmann S, Sallas WM, Machevo S, et al. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem®) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Inter Health. 2010;15(4):434–41.
Slutsker LM, Khoromana CO, Payne D, et al. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ. 1990;68(1):53–9.
Karunajeewa HA, Ilett KF, Mueller I, et al. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother. 2008;52(1):237–43.
Wilson AL, on behalf of the IPTc Taskforce. A systematic review and meta-analysis of the efficacy and safety of intermittent preventative treatment of malaria in children (IPTc). PLoS One. 2011;6(2):e16976.
Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67.
Acknowledgments
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pawluk, S.A., Wilby, K.J. & Ensom, M.H.H. Pharmacokinetic Profile of Artemisinin Derivatives and Companion Drugs Used in Artemisinin-Based Combination Therapies for the Treatment of Plasmodium falciparum Malaria in Children. Clin Pharmacokinet 52, 153–167 (2013). https://doi.org/10.1007/s40262-012-0026-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-012-0026-5